Co-Authors
This is a "connection" page, showing publications co-authored by KHANDAN KEYOMARSI and ISABELLE BEDROSIAN.
Connection Strength
1.273
-
Cyclin E-associated kinase activity predicts response to platinum-based chemotherapy. Clin Cancer Res. 2007 Aug 15; 13(16):4800-6.
Score: 0.315
-
Cyclin E deregulation alters the biologic properties of ovarian cancer cells. Oncogene. 2004 Apr 08; 23(15):2648-57.
Score: 0.249
-
Cyclin E in breast cancer. N Engl J Med. 2003 Mar 13; 348(11):1063-4; author reply 1063-4.
Score: 0.232
-
Cyclin E is a more powerful predictor of breast cancer outcome than proliferation. Nat Med. 2003 Feb; 9(2):152.
Score: 0.230
-
Cyclin E deregulation is an early event in the development of breast cancer. Breast Cancer Res Treat. 2009 Jun; 115(3):651-9.
Score: 0.086
-
The tumor-specific hyperactive forms of cyclin E are resistant to inhibition by p21 and p27. J Biol Chem. 2005 Apr 15; 280(15):15148-57.
Score: 0.066
-
The low molecular weight (LMW) isoforms of cyclin E deregulate the cell cycle of mammary epithelial cells. Cell Cycle. 2003 Sep-Oct; 2(5):461-6.
Score: 0.060
-
Anti-HER2 antibody trastuzumab inhibits CDK2-mediated NPAT and histone H4 expression via the PI3K pathway. Cell Cycle. 2006 Aug; 5(15):1654-61.
Score: 0.018
-
Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. Proc Natl Acad Sci U S A. 2005 Aug 30; 102(35):12519-24.
Score: 0.017